Pneumococcal vaccination in developing countries: where does science end and commerce begin?
Recently Pneumococcal vaccines have generated considerable interest in developing countries as an intervention for protecting children from pneumonia and thereby reducing childhood mortality. Many convincing scientific arguments have been put forward, although they are often based either on extension of information from developed countries, or estimation plus extrapolation of limited local data. In addition, there is also significant commercial pressure to prescribe/recommend Pneumococcal vaccine(s). Against such a background, it is important for developing countries to critically appraise the issues involved in order to make a rational choice. This brief paper explores these issues, showing that the current Pneumococcal vaccines have limited effectiveness in developing countries and the hype surrounding them is more commercial than scientific.
Mathew
Joseph L
JL
Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. jlmathew@rediffmail.com
D002648:Child; D002675:Child, Preschool; D003906:Developing Countries; D006801:Humans; D007223:Infant; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D016896:Treatment Outcome; D014611:Vaccination / Q000706:statistics & numerical data*
D022242:Pneumococcal Vaccines